Find Reports
Select Report Type
Reimbursement Review
Displaying 101 - 125 of 1258
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Yescarta | axicabtagene ciloleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0314-000 | |||
| N/A | rivaroxaban | Venous thromboembolic events (VTE) | Reimburse with clinical criteria and/or conditions | Complete | SX0750-000 - SR0750-000 | |||
| Imbruvica | ibrutinib | Chronic lymphocytic leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | PC0317-000 | |||
| Imcivree | setmelanotide | Bardet-Biedl syndrome | Reimburse with clinical criteria and/or conditions | Complete | SR0769-000 | |||
| Dupixent | dupilumab | Atopic dermatitis, pediatrics | Reimburse with clinical criteria and/or conditions | Complete | SR0774-000 | |||
| Atriance | nelarabine | T-cell acute lymphoblastic leukemia | Reimburse with clinical criteria and/or conditions | Complete | PC0307-000 | |||
| N/A | abiraterone, prednisone, docetaxel | Metastatic castration sensitive prostate cancer (mCSPC) | Reimburse | Complete | PX0298-000 - PC0298-000 | |||
| n/a | abiraterone acetate and prednisolone | High-risk non-metastatic prostate cancer | Reimburse with clinical criteria and/or conditions | Complete | PX0291-000 - PC0291-000 | |||
| Rinvoq | upadacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | SR0730-000 | |||
| Kymriah | tisagenlecleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | PG0306-000 | |||
| Brukinsa | zanubrutinib | Chronic lymphocytic leukemia /small lymphocytic lymphoma. | Reimburse with clinical criteria and/or conditions | Complete | PC0310-000 | |||
| Welireg | belzutifan | von Hippel-Lindau disease-associated tumours | Reimburse with clinical criteria and/or conditions | Complete | PC0309-000 | |||
| Xcopri | cenobamate | Epilepsy, partial-onset seizures | Reimburse with clinical criteria and/or conditions | Complete | SR0770-000 | |||
| N/A | dapagliflozin | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | SX0749-000 - SR0749-000 | |||
| Zoryve | roflumilast | Plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | SR0771-000 | |||
| Tavneos | avacopan | Antineutrophil cytoplasmic antibody-associated vasculitis | Do not reimburse | Complete | SR0732-000 | |||
| Vraylar | cariprazine | Schizophrenia | Do not reimburse | Complete | SR0708-000 | |||
| Sotyktu | deucravacitinib | Psoriasis, moderate to severe plaque | Do not reimburse | Complete | SR0756-000 | |||
| Ultomiris | ravulizumab | AChR antibody-positive generalized Myasthenia Gravis | Do not reimburse | Complete | SR0765-000 | |||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | SR0752-000 | |||
| Enhertu | trastuzumab deruxtecan | unresectable or metastatic HER2-low breast cancer | Reimburse with clinical criteria and/or conditions | Complete | PC0305-000 | |||
| Vyalev | foslevodopa foscarbidopa | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | SR0768-000 | |||
| Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | SR0724-000 | |||
| Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | SR0758-000 | |||
| Skyrizi | risankizumab | Crohn's disease | Reimburse with clinical criteria and/or conditions | Complete | SR0767-000 |
Health Technology Review
Displaying 101 - 125 of 589
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Clinical and Instrumental Swallowing Assessments for Dysphagia | Rapid Review | Completed | RC1526-000 | |||
| Calcitonin Gene-Related Peptide Inhibitors for Migraine Prophylaxis | Technology Review | In Progress | HC0081-000 | |||
| Average Volume of MRI Exams Conducted per Hour Across Canada | Using data from the national Canadian Medical Imaging Inventory 2019 to 2020 survey, we calculated an average of MRI exams performed per hour across Canada | CMII Service | Completed | CM0008-000 | ||
| Biologic Drugs for Severe Asthma | Technology Review | Completed | RE0047-000 | |||
| Buprenorphine Formulations for Opioid Use Disorder | Systematic Review | Completed | RE0051-000 | |||
| The Safety of Niraparib in Ovarian Cancer | To give clinicians and policy-makers a better understanding of the niraparib’s risk profile, researchers conducted an observational study to look at how the safety and tolerability of niraparib in the real world compares with observations from seminal clinical trials. | Observational Study | Active | OS0002-000 | ||
| Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update | We conducted a review of the clinical effectiveness, cost-effectiveness, and evidence-based guidelines on the use of ketamine in adults with TRD or PTSD, to help guide decisions on the use of ketamine for managing these conditions. | Rapid Review | Completed | RC1522-000 | ||
| Endobronchial Valves for the Management of Severe Emphysema | Rapid Review | Completed | RC1524-000 | |||
| Ketorolac for Renal Colic | Rapid Review | Completed | RC1525-000 | |||
| Immune checkpoint inhibitors for mutated non–small cell lung cancer | Observational Study | In Progress | OS0008-000 | |||
| Leucovorin Dosing for Gastrointestinal Cancer | Rapid Review | Completed | RC1518-000 | |||
| Ketamine for Chronic Non-Cancer Pain: A 2023 Update | Summary with Critical Appraisal | Completed | RC1521-000 | |||
| Screening for Colorectal Cancer in Individuals Younger Than 50 Years | Rapid Review with Expert Input | Completed | RD0069-000 | |||
| Perspectives and Experiences Regarding the Creation of Arteriovenous Fistulas for Hemodialysis Access: A Rapid Qualitative Review | Rapid Review | Completed | RC1519-000 | |||
| Hernia Support Garments for Parastomal Hernia Following Ostomy Procedure | Rapid Review | Completed | RC1520-000 | |||
| ChatGPT in Radiology: Appropriate Imaging and Workflow Efficiencies | CMII Service | Completed | CM0009-000 | |||
| Early Intervention Programs for Adolescents and Young Adults With Eating Disorders | Health Technology Assessment | Completed | HT0040-000 - OP0552-000 | |||
| Aging in Place | Our Health Technology Expert Review Panel convened to develop objective, impartial, trusted pan-Canadian guidance to inform decisions about which evidence-informed, equitable, aging in place initiatives across jurisdictions can support aging in place in Canada. | Optimal Use | Active | OP0555-000 | ||
| Pathology Implementation Advice Panel: Guidance for Reporting Diagnostic Classifications for Breast Cancer | Technology Review | Completed | HC0070-000 | |||
| An Analysis of Demographic and Utilization Patterns of Patients Accessing Emergency Departments in Canada | Technology Review | Complete | HC0061-000 | |||
| Emergency Department Overcrowding in Canada: An Update |
CADTH Guidance: Emergency Department OvercrowdingContributing Factors and Intervention EffectivenessSupporting Information: Factors and Intervention EffectivenessMultistakeholder DialogueProtocol: Contributing Factors and Intervention EffectivenessEvidence Preview: Factors and Intervention Effectiveness |
Optimal Use | Completed | OP0553-000 - RE0044-000 | ||
| Case Carts in Surgical Settings | Rapid Review | Completed | RC1512-000 | |||
| Routine Dental Polishing for Oral Health | Rapid Review | Completed | RC1517-000 | |||
| Intrathecal Drug Delivery Systems for Cancer Pain | Technology Review | Completed | HC0058-000 | |||
| Buprenorphine Naloxone Film versus Tablets for Opioid Use Disorder | CADTH's Health Technology Review identifies and summarizes literature comparing the effectiveness and cost-effectiveness of sublingual buprenorphine-naloxone films versus tablets. | Rapid Review | Completed | RC1513-000 |
Horizon Scan
Displaying 101 - 111 of 111
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|
| Health Technology Update - Issue 25 | Completed | EN0015-000 | ||||
| Dementia Villages | Emerging Health Technologies | Completed | EH0071-000 | |||
| Dementia Villages - Position Statement | EH0071-000 | |||||
| Dementia Villages: Innovative Residential Care for People With Dementia | EH0071-000 | |||||
| Health Technology Update — Issue 24 | Health Technology Update | Completed | EN0014-000 | |||
| Esketamine for Treatment-Resistant Depression | EH0075-000 | |||||
| Horizon Scan Roundup — 2018 | ER0007-000 | |||||
| Health Technology Update — Issue 23 | Health Technology Update | Completed | EN0013-000 | |||
| An Overview of Clinical Applications of Artificial Intelligence | Emerging Health Technologies | Completed | EH0070-000 | |||
| Alternating Electric Fields ("Tumour- Treating Fields") for the Treatment of Glioblastoma | Emerging Health Technologies | Completed | EH0060-000 | |||
| Buprenorphine Implant for the Treatment of Opioid Use Disorder | Completed | EH0044-000 |
Projects in Progress
Displaying 26 - 40 of 40
View All Reports
Displaying 101 - 125 of 2093
Please scroll or swipe to the right to view the full content.
| Title | Description | Files | Last Updated Sort ascending | Project Line | Project Sub Line | Status | Project Number |
|---|---|---|---|---|---|---|---|
| dabrafenib-trametinib | Reimbursement Review | Active | PX0375-000 | ||||
| regorafenib | Reimbursement Review | Active | PX0374-000 | ||||
| spesolimab | Reimbursement Review | Active | SR0844-000 | ||||
| delgocitinib | Reimbursement Review | Received | SR0875-000 | ||||
| isatuximab | Reimbursement Review | Active | PC0378-000 | ||||
| lebrikizumab | Reimbursement Review | Active | SR0819-000 | ||||
| ferric carboxymaltose | Reimbursement Review | Active | SR0842-000 | ||||
| pembrolizumab | Reimbursement Review | Active | PC0385-000 | ||||
| exagamglogene autotemcel | Reimbursement Review | Active | SG0831-000 | ||||
| exagamglogene autotemcel | Reimbursement Review | Active | SG0830-000 | ||||
| capivasertib | Reimbursement Review | Complete | PC0341-000 | ||||
| cipaglucosidase alfa and miglustat | Reimbursement Review | Active | SR0871-000 | ||||
| elafibranor | Reimbursement Review | Active | SR0865-000 | ||||
| quizartinib | Reimbursement Review | Active | PC0359-000 | ||||
| Large B cell lymphoma | Reimbursement Review | Provisional Funding Algorithm | Open for Stakeholder Feedback | PH0064-000 | |||
| Colorectal cancer | Reimbursement Review | Provisional Funding Algorithm | Open for Stakeholder Feedback | PH0062-000 | |||
| clindamycin plus benzoyl peroxide and adapalene | Reimbursement Review | Active | SR0794-000 | ||||
| osimertinib | Reimbursement Review | Pending | PC0398-000 | ||||
| elexacaftor/tezacaftor/ivacaftor and ivacaftor | Reimbursement Review | Active | SR0837-000 | ||||
| venetoclax | Reimbursement Review | Active | PC0362-000 | ||||
| talquetamab | Reimbursement Review | Active | PC0363-000 | ||||
| lisocabtagene maraleucel | Reimbursement Review | Active | PG0358-000 | ||||
| fruquintinib | Reimbursement Review | Active | PC0352-000 | ||||
| semaglutide | Reimbursement Review | Active | SR0841-000 | ||||
| guselkumab | Reimbursement Review | Active | SR0874-000 |